Responses Needed By July 29, 2022 Telling your story helps bring the Leber congenital amaurosis (LCA) community together. It also helps rare retinal disease advocates like us at Hope in […]
We’ve heard a lot about therapies to correct mutations in specific genes causing blindness or low vision, and now research is moving beyond single-gene correction to gene-independent therapies to [...]
Innovative funding initiatives created by the Foundation Fighting Blindness are accelerating research advances to find treatments for Leber congenital amaurosis (LCA) and other rare inherited [...]
Foundation Fighting Blindness begins its VISIONS 2022 national conference tomorrow, and Hope in Focus will be there to hear the latest research advances for Leber congenital amaurosis (LCA) and [...]
David Schulz has been appointed to our Board of Directors. He began his career at Pfizer Central Research as a Research Scientist in 1989 and was promoted to Executive Director […]
ProQR Therapeutics completed an in-depth strategic review to prioritize its objectives toward advancing RNA therapies, following news that its Illuminate Phase 2/3 clinical trial of sepofarsen in [...]
Working with preclinical data from multiple Leber congenital amaurosis (LCA) studies at the same time, Opus Genetics hopes to advance research into gene therapy for several forms of LCA at a [...]
Children living with visual impairment become more independent and empowered when parents set high expectations for their kids and challenge them every day. Just ask Beth Borysewicz. In her role [...]
After crazy months of looking for answers to questions about her infant’s vision, Melissa Matias learned her baby girl, Dylan, had a form of Leber congenital amaurosis known as LCA6 caused […]
ProQR Therapeutics’ clinical trials of sepofarsen to treat a form of Leber congenital amaurosis (LCA) caused by a mutation in the CEP290 gene did not meet its primary endpoint of […]
